Author: Vima Therapeutics

Vima Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial for Parkinson’s Disease Tremor Insufficiently Responsive to Dopaminergic Therapy

November 5, 2026
Vima Therapeutics to Present New Research at the 2026 International Congress of Parkinson’s Disease and Movement Disorders

October 1, 2026

Vima Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial for Parkinson’s Disease Tremor Insufficiently Responsive to Dopaminergic Therapy